| Bioactivity | HSP90-IN-31 (compound Be01) causes reduction of CD80 and CD86 expression on dendritic cells (DCs). HSP90-IN-31 decreases the production of pro-inflammatory cytokines (IL-6, TNF-α, and IL-1β) in BMDC and peritoneal macrophages stimulated by LPS (HY-D1056). Under the delayed-type hypersensitivity (DTH) mice model, HSP90-IN-31 reduces ear swelling and pro-inflammatory cytokines in the spleen[1]. |
| CAS | 2117645-10-8 |
| Formula | C22H28N2O4 |
| Molar Mass | 384.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hyun Bo Sim, et al. Development of Hsp90 inhibitor to regulate cytokine storms in excessive delayed- and acute inflammation. Int Immunopharmacol. 2024 Aug 20:137:112470. |
HSP90-IN-31
CAS: 2117645-10-8 F: C22H28N2O4 W: 384.47
HSP90-IN-31 (compound Be01) causes reduction of CD80 and CD86 expression on dendritic cells (DCs). HSP90-IN-31 decreases
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.